{"id":"NCT02815670","sponsor":"Boehringer Ingelheim","briefTitle":"Reversal Dabigatran Anticoagulant Effect With Idarucizumab","officialTitle":"Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-07","primaryCompletion":"2019-10-19","completion":"2019-10-19","firstPosted":"2016-06-28","resultsPosted":"2020-04-14","lastUpdate":"2020-04-14"},"enrollment":1,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemorrhage"],"interventions":[{"type":"DRUG","name":"Idarucizumab","otherNames":[]}],"arms":[{"label":"Idarucizumab","type":"EXPERIMENTAL"}],"summary":"The trial objective is to demonstrate the safety of idarucizumab, as assessed by the occurence of patients with drug related adverse events (including immune reactions) and all-cause mortality in paediatric venous thromboembolism patients treated with dabigatran in ongoing clinical trials who require emergency surgery/urgent procedures or patients who have life-threatening or uncontrolled bleeding which requires urgent intervention, when rapid reversal of the anticoagulant effect of dabigatran is needed.","primaryOutcome":{"measure":"Number of Participants With Drug-related Adverse Events (AEs)","timeFrame":"From vial 1 of Idarucizumab until prematurely discontinued of the trial, up to 25 days","effectByArm":[{"arm":"Idarucizumab","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":9},"locations":{"siteCount":2,"countries":["Russia"]},"refs":{"pmids":["30046708"],"seeAlso":["https://trials.boehringer-ingelheim.com/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":1},"commonTop":["Thrombocytopenia"]}}